Literature DB >> 26970271

Dual mechanisms of action of the RNA-binding protein human antigen R explains its regulatory effect on melanoma cell migration.

Farnaz Moradi1, Pontus Berglund1, Rickard Linnskog1, Karin Leandersson2, Tommy Andersson1, Chandra Prakash Prasad3.   

Abstract

Overexpression of wingless-type MMTV integration site family 5A (WNT5A) plays a significant role in melanoma cancer progression; however, the mechanism(s) involved remains unknown. In breast cancer, the human antigen R (HuR) has been implicated in the regulation of WNT5A expression. Here, we demonstrate that endogenous expression of WNT5A correlates with levels of active HuR in HTB63 and WM852 melanoma cells and that HuR binds to WNT5A messenger RNA in both cell lines. Although the HuR inhibitor MS-444 significantly impaired migration in both melanoma cell lines, it reduced WNT5A expression only in HTB63 cells, as did small interfering RNA knockdown of HuR. Consistent with this finding, MS-444-induced inhibition of HTB63 cell migration was restored by the addition of recombinant WNT5A, whereas MS-444-induced inhibition of WM852 cell migration was restored by the addition of recombinant matrix metalloproteinase-9, another HuR-regulated protein. Clearly, HuR positively regulates melanoma cell migration via at least 2 distinct mechanisms making HuR an attractive therapeutic target for halting melanoma dissemination.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26970271     DOI: 10.1016/j.trsl.2016.02.007

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  7 in total

1.  Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells.

Authors:  Jiping Wang; Anita B Hjelmeland; L Burt Nabors; Peter H King
Journal:  Cancer Biol Ther       Date:  2019-04-16       Impact factor: 4.742

2.  Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors.

Authors:  Natalia Filippova; Xiuhua Yang; Subramaniam Ananthan; Jennifer Calano; Vibha Pathak; Larry Bratton; Rakesh H Vekariya; Sixue Zhang; Edward Ofori; Emily N Hayward; David Namkoong; David K Crossman; Michael R Crowley; Peter H King; James Mobley; Louis B Nabors
Journal:  Cancer Res       Date:  2021-02-18       Impact factor: 13.312

3.  HuRdling Senescence: HuR Breaks BRAF-Induced Senescence in Melanocytes and Supports Melanoma Growth.

Authors:  Janika K Liebig; Silke Kuphal; Anja Katrin Bosserhoff
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

Review 4.  RNA-Targeted Therapies and High-Throughput Screening Methods.

Authors:  Siran Zhu; Saul Rooney; Gracjan Michlewski
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

5.  MiR-155 Regulates PAD4-Dependent Formation of Neutrophil Extracellular Traps.

Authors:  Avin Hawez; Amr Al-Haidari; Raed Madhi; Milladur Rahman; Henrik Thorlacius
Journal:  Front Immunol       Date:  2019-11-01       Impact factor: 7.561

6.  ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.

Authors:  Ya-Ping Pei; Yue-Yi Wang; Dan Liu; Hui-Yang Lei; Zhi-Hao Yang; Zi-Wei Zhang; Man Han; Ke Cheng; Yu-Shan Chen; Jin-Quan Li; Gui-Rong Cheng; Lang Xu; Qing-Ming Wu; Shawn M McClintock; Ying Yang; Yong Zhang; Yan Zeng
Journal:  J Neurosci       Date:  2019-12-27       Impact factor: 6.167

7.  Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment.

Authors:  Narsireddy Amreddy; Anish Babu; Janani Panneerselvam; Akhil Srivastava; Ranganayaki Muralidharan; Allshine Chen; Yan D Zhao; Anupama Munshi; Rajagopal Ramesh
Journal:  Nanomedicine       Date:  2017-11-16       Impact factor: 5.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.